Journal Watch · Clinical Cancer Research · 2026

A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.

The PFS rate at 4 months in the DDR and IDH1 cohorts was longer than expected and supports further investigation of the addition of a PARP inhibitor during maintenance immune checkpoint inhibition for DDR and IDH1-altered patients with BTC.

Mohan A, Griffith KA, Goff LW et al.Clinical Cancer Research3 min readPharma relevance 95/100

DOI: 10.1158/1078-0432.ccr-25-1114PMID: 42489677Study type: randomised / controlled clinical trial

TL;DR

The PFS rate at 4 months in the DDR and IDH1 cohorts was longer than expected and supports further investigation of the addition of a PARP inhibitor during maintenance immune checkpoint inhibition for DDR and IDH1-altered patients with BTC.

Key findings

  • Two (6.4%) patients had a partial response.
  • The most common grade ≥3 treatment-related adverse events included anemia (12.9%), neutropenia (9.7%), and elevated liver enzymes (12.9%).<h4>Conclusions</h4>The primary endpoint of the PFS rate at 4 months was not met.
  • The PFS rate at 4 months in the DDR and IDH1 cohorts was longer than expected and supports further investigation of the addition of a PARP inhibitor during maintenance immune checkpoint inhibition for DDR and IDH1-altered patients with BTC.

Numbers at a glance (from the abstract)

n = 363%85%77.6%71%29%54.8%95%83.3%100%6.4%12.9%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Four-month PFS rate was 54.8% [95% confidence intervals (CI), 36-72.7] in all patients and 83.3% and 100% in the DDR and IDH1 cohorts, respectively. Median PFS1 and OS1 were 4.6 months (95% CI, 3.7-6.2) and 15.9 months (95% CI, 9.8-24.1), respectively. Median PFS2 and OS2 were 9.9 months (95% CI, 8.3-11.3) and 21.4 months (95% CI, 14.8-26.7), respectively.

Full abstract (original)

Background: <h4>Purpose</h4>This phase II trial investigated rucaparib [poly (ADP-ribose) polymerase (PARP) inhibitor] in combination with nivolumab in patients with advanced biliary tract cancer (BTC) without progression after 4 to 6 months of first-line platinum-based chemotherapy.<h4>Patients and methods</h4>The primary endpoint was the 4-month progression-free survival (PFS) rate with null and alternative hypotheses of 63% and 85%. Secondary endpoints included the PFS rate in patients with DNA damage response (DDR) and isocitrate dehydrogenase 1 (IDH1) mutations, median PFS and overall survival (OS) from the start of study treatment (PFS1 and OS1) and first-line chemotherapy (PFS2 and OS2), best overall response, and safety (NCT03639935).<h4>Results</h4>Of 31 patients, 24 (77.6%) had Eastern Cooperative Oncology Group performance status 1, and 22 (71%) had intrahepatic cholangiocarcinoma. Nine (29%) patients had DDR or IDH1 mutations [BRCA2 (n = 3), ATM (2), FANCA (1), and IDH1 (3)].

What they did: Four-month PFS rate was 54.8% [95% confidence intervals (CI), 36-72.7] in all patients and 83.3% and 100% in the DDR and IDH1 cohorts, respectively. Median PFS1 and OS1 were 4.6 months (95% CI, 3.7-6.2) and 15.9 months (95% CI, 9.8-24.1), respectively. Median PFS2 and OS2 were 9.9 months (95% CI, 8.3-11.3) and 21.4 months (95% CI, 14.8-26.7), respectively.

Results & conclusions: Two (6.4%) patients had a partial response. The most common grade ≥3 treatment-related adverse events included anemia (12.9%), neutropenia (9.7%), and elevated liver enzymes (12.9%).<h4>Conclusions</h4>The primary endpoint of the PFS rate at 4 months was not met. The PFS rate at 4 months in the DDR and IDH1 cohorts was longer than expected and supports further investigation of the addition of a PARP inhibitor during maintenance immune checkpoint inhibition for DDR and IDH1-altered patients with BTC.

Abstract © the authors / Clinical Cancer Research (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1158/1078-0432.ccr-25-1114 · PubMed 42489677.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Clinical Cancer Research study find?

The PFS rate at 4 months in the DDR and IDH1 cohorts was longer than expected and supports further investigation of the addition of a PARP inhibitor during maintenance immune checkpoint inhibition for DDR and IDH1-altered patients with BTC.

What type of study is this?

It is a randomised / controlled clinical trial, published in Clinical Cancer Research in 2026. Four-month PFS rate was 54.8% [95% confidence intervals (CI), 36-72.7] in all patients and 83.3% and 100% in the DDR and IDH1 cohorts, respectively.

Where can I read the original paper?

The original is at the publisher via DOI 10.1158/1078-0432.ccr-25-1114. PubMed ID: 42489677. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Mohan A, Griffith KA, Goff LW et al.. A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.. Clinical Cancer Research (2026). DOI: 10.1158/1078-0432.ccr-25-1114.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-phase-ii-multicenter-trial-of-rucaparib-and-nivolumab-as-maintenance-t-251114/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides